3.62
+0.19(+5.54%)
Currency In USD
| Previous Close | 3.43 |
| Open | 3.45 |
| Day High | 3.69 |
| Day Low | 3.43 |
| 52-Week High | 4.02 |
| 52-Week Low | 2.46 |
| Volume | 379,362 |
| Average Volume | 422,688 |
| Market Cap | 282.82M |
| PE | -2.05 |
| EPS | -1.77 |
| Moving Average 50 Days | 3.17 |
| Moving Average 200 Days | 3.18 |
| Change | 0.19 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $119.31 as of December 24, 2025 at a share price of $3.62. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $828.38 as of December 24, 2025 at a share price of $3.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewswire Inc.
Dec 22, 2025 12:00 PM GMT
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-20
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 07, 2025 1:00 PM GMT
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery